New Data at EADV 2020 Confirm Taltz® (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis

- Long-term and post-hoc analysis data show continued efficacy of Taltz in treating challenging body areas, including scalp, nails, palms and soles - INDIANAPOLIS , Oct. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz ® (ixekizumab) data from